|
US3862925A
(en)
|
1973-07-05 |
1975-01-28 |
American Home Prod |
Preparation of somatotropin release inhibiting factor and intermediates therefor
|
|
US3842067A
(en)
|
1973-07-27 |
1974-10-15 |
American Home Prod |
Synthesis of(des-asn5)-srif and intermediates
|
|
JPS5726506B2
(enExample)
|
1974-03-08 |
1982-06-04 |
|
|
|
US4105603A
(en)
|
1977-03-28 |
1978-08-08 |
The Salk Institute For Biological Studies |
Peptides which effect release of hormones
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4752601A
(en)
|
1983-08-12 |
1988-06-21 |
Immunetech Pharmaceuticals |
Method of blocking immune complex binding to immunoglobulin FC receptors
|
|
US5807715A
(en)
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
|
US5985599A
(en)
|
1986-05-29 |
1999-11-16 |
The Austin Research Institute |
FC receptor for immunoglobulin
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
CA1338518C
(en)
|
1987-09-23 |
1996-08-13 |
Joyce M. Zarling |
Antibody heteroconjugates for the killing of hiv-infected cells
|
|
JP3095168B2
(ja)
|
1988-02-05 |
2000-10-03 |
エル． モリソン，シェリー |
ドメイン‐変性不変部を有する抗体
|
|
US5169933A
(en)
|
1988-08-15 |
1992-12-08 |
Neorx Corporation |
Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
|
|
US5576184A
(en)
|
1988-09-06 |
1996-11-19 |
Xoma Corporation |
Production of chimeric mouse-human antibodies with specificity to human tumor antigens
|
|
DE68928427T2
(de)
|
1988-09-15 |
1998-06-04 |
Univ Columbia |
Antikörper mit modifiziertem Kohlenhydratgehalt und Verfahren zur Herstellung und Verwendung
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5116964A
(en)
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
|
GB8916400D0
(en)
|
1989-07-18 |
1989-09-06 |
Dynal As |
Modified igg3
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
US5364930A
(en)
|
1990-10-16 |
1994-11-15 |
Northwestern University |
Synthetic C1q peptide fragments
|
|
GB9105245D0
(en)
|
1991-03-12 |
1991-04-24 |
Lynxvale Ltd |
Binding molecules
|
|
US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
|
US5223408A
(en)
|
1991-07-11 |
1993-06-29 |
Genentech, Inc. |
Method for making variant secreted proteins with altered properties
|
|
CA2078539C
(en)
|
1991-09-18 |
2005-08-02 |
Kenya Shitara |
Process for producing humanized chimera antibody
|
|
ES2136092T3
(es)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
Procedimientos para la produccion de anticuerpos humanizados.
|
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
|
AU4116793A
(en)
|
1992-04-24 |
1993-11-29 |
Board Of Regents, The University Of Texas System |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
|
GB9225453D0
(en)
|
1992-12-04 |
1993-01-27 |
Medical Res Council |
Binding proteins
|
|
DE69433279T2
(de)
|
1993-02-10 |
2004-07-15 |
Unilever N.V. |
Isolierungsverfahren verwendend immobilisierte proteine mit spezifischen bindungskapazitäten
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
US5874239A
(en)
|
1993-07-30 |
1999-02-23 |
Affymax Technologies N.V. |
Biotinylation of proteins
|
|
GB9316989D0
(en)
|
1993-08-16 |
1993-09-29 |
Lynxvale Ltd |
Binding molecules
|
|
DK0759944T3
(da)
|
1994-05-13 |
2001-11-26 |
Biovation Ltd |
Forbedringer af og relateret til peptidfremføring
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US6265150B1
(en)
|
1995-06-07 |
2001-07-24 |
Becton Dickinson & Company |
Phage antibodies
|
|
US6750334B1
(en)
|
1996-02-02 |
2004-06-15 |
Repligen Corporation |
CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
|
|
CA2249195A1
(en)
|
1996-03-18 |
1997-09-25 |
Board Of Regents, The University Of Texas System |
Immunoglobin-like domains with increased half lives
|
|
US5834597A
(en)
|
1996-05-20 |
1998-11-10 |
Protein Design Labs, Inc. |
Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
|
|
US6300065B1
(en)
|
1996-05-31 |
2001-10-09 |
Board Of Trustees Of The University Of Illinois |
Yeast cell surface display of proteins and uses thereof
|
|
US6699658B1
(en)
|
1996-05-31 |
2004-03-02 |
Board Of Trustees Of The University Of Illinois |
Yeast cell surface display of proteins and uses thereof
|
|
AU3968897A
(en)
|
1996-08-02 |
1998-02-25 |
Bristol-Myers Squibb Company |
A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
|
|
US6025485A
(en)
|
1997-02-14 |
2000-02-15 |
Arcaris, Inc. |
Methods and compositions for peptide libraries displayed on light-emitting scaffolds
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
US6090381A
(en)
|
1997-02-11 |
2000-07-18 |
Immunomedics, Inc. |
Stimulation of an immune response with antibodies labeled with the . .alpha-galactosyl epitope
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
US20030207346A1
(en)
|
1997-05-02 |
2003-11-06 |
William R. Arathoon |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
EP0979281B1
(en)
|
1997-05-02 |
2005-07-20 |
Genentech, Inc. |
A method for making multispecific antibodies having heteromultimeric and common components
|
|
DE19721700C1
(de)
|
1997-05-23 |
1998-11-19 |
Deutsches Krebsforsch |
Mutierter OKT3-Antikörper
|
|
BR9908226A
(pt)
|
1998-02-25 |
2000-10-24 |
Lexigen Pharm Corp |
Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo
|
|
US6455263B2
(en)
|
1998-03-24 |
2002-09-24 |
Rigel Pharmaceuticals, Inc. |
Small molecule library screening using FACS
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
CA2323757C
(en)
|
1998-04-02 |
2011-08-02 |
Genentech, Inc. |
Antibody variants and fragments thereof
|
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
SE9802213D0
(sv)
|
1998-06-18 |
1998-06-18 |
Amersham Pharm Biotech Ab |
A method for the removal/purification of serum albumins and means for use in the method
|
|
US6727349B1
(en)
|
1998-07-23 |
2004-04-27 |
Millennium Pharmaceuticals, Inc. |
Recombinant anti-CCR2 antibodies and methods of use therefor
|
|
JP2002522063A
(ja)
|
1998-08-17 |
2002-07-23 |
アブジェニックス インコーポレイテッド |
増加した血清半減期を有する改変された分子の生成
|
|
US7315786B2
(en)
|
1998-10-16 |
2008-01-01 |
Xencor |
Protein design automation for protein libraries
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
HUP0104865A3
(en)
|
1999-01-15 |
2004-07-28 |
Genentech Inc |
Polypeptide variants with altered effector function
|
|
US7527787B2
(en)
|
2005-10-19 |
2009-05-05 |
Ibc Pharmaceuticals, Inc. |
Multivalent immunoglobulin-based bioactive assemblies
|
|
DE19937264A1
(de)
|
1999-08-06 |
2001-02-15 |
Deutsches Krebsforsch |
F¶v¶-Antikörper-Konstrukte
|
|
AU2001233277B2
(en)
|
2000-02-03 |
2004-06-03 |
Millennium Pharmaceuticals, Inc. |
Humanized anti-ccr2 antibodies and methods of use therefor
|
|
EP1266014A2
(en)
|
2000-03-24 |
2002-12-18 |
Peter Kufer |
Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
|
|
AU2001270609A1
(en)
|
2000-06-30 |
2002-01-14 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Heterodimeric fusion proteins
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
EP1355919B1
(en)
|
2000-12-12 |
2010-11-24 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
|
CA2444680A1
(en)
|
2001-04-18 |
2002-10-31 |
Dyax Corp. |
Binding molecules for fc-region polypeptides
|
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
|
JP4381140B2
(ja)
|
2001-10-12 |
2009-12-09 |
シェーリング コーポレイション |
免疫応答を調節するための二重特異性抗体の使用
|
|
AU2002337885B1
(en)
|
2001-10-16 |
2003-04-28 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Broadly cross-reactive neutralizing antibodies against human ummunodeficiency virus selected by Env-CD4-co-receptor complexes
|
|
PL213948B1
(pl)
|
2001-10-25 |
2013-05-31 |
Genentech Inc |
Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
|
|
US20050142539A1
(en)
|
2002-01-14 |
2005-06-30 |
William Herman |
Targeted ligands
|
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
AU2003217912A1
(en)
|
2002-03-01 |
2003-09-16 |
Xencor |
Antibody optimization
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
EP1354600A1
(en)
|
2002-04-19 |
2003-10-22 |
Affimed Therapeutics AG |
Antibody combination useful for tumor therapy
|
|
AU2003233197A1
(en)
|
2002-04-29 |
2003-11-17 |
Genpat77 Pharmacogenetics Ag |
Novel antibody binding tcr and tirc7 and its use in therapy and diagnosis
|
|
CA2487932A1
(en)
|
2002-05-30 |
2003-12-11 |
Macrogenics, Inc. |
Cd16a binding proteins and use for the treatment of immune disorders
|
|
US20040071705A1
(en)
|
2002-06-21 |
2004-04-15 |
Dyax Corporation |
Serum protein-associated target-specific ligands and identification method therefor
|
|
PT1534335E
(pt)
|
2002-08-14 |
2012-02-28 |
Macrogenics Inc |
Anticorpos específicos de fcγriib e processos para a sua utilização
|
|
US8187593B2
(en)
|
2002-08-14 |
2012-05-29 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8044180B2
(en)
|
2002-08-14 |
2011-10-25 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8193318B2
(en)
|
2002-08-14 |
2012-06-05 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
CA2832136C
(en)
|
2002-09-27 |
2015-11-17 |
Xencor |
Optimized fc variants and methods for their generation
|
|
US9701754B1
(en)
|
2002-10-23 |
2017-07-11 |
City Of Hope |
Covalent disulfide-linked diabodies and uses thereof
|
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
US7355008B2
(en)
|
2003-01-09 |
2008-04-08 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
AU2004204817C1
(en)
|
2003-01-13 |
2011-01-20 |
Macrogenics, Inc. |
Soluble FcyR fusion proteins and methods of use thereof
|
|
DE10303664A1
(de)
|
2003-01-23 |
2004-08-12 |
Nemod Immuntherapie Ag |
Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
|
|
AU2004242845B2
(en)
|
2003-05-31 |
2011-06-02 |
Amgen Research (Munich) Gmbh |
Human-anti-human CD3 binding molecules
|
|
CA2531118C
(en)
|
2003-07-01 |
2013-01-08 |
Immunomedics, Inc. |
Multivalent carriers of bi-specific antibodies
|
|
DE10346627A1
(de)
|
2003-10-08 |
2005-05-19 |
Weiss, Stefan, PD Dr. |
Single-chain-Antikörper gegen den 37 kDa/67 kDa Lamininrezeptor als Werkzeuge zur Diagnose und Therapie von Prionerkrankungen und Krebs, deren Herstellung und Verwendung
|
|
EP1697520A2
(en)
|
2003-12-22 |
2006-09-06 |
Xencor, Inc. |
Fc polypeptides with novel fc ligand binding sites
|
|
US7235641B2
(en)
|
2003-12-22 |
2007-06-26 |
Micromet Ag |
Bispecific antibodies
|
|
JP4762156B2
(ja)
|
2004-01-12 |
2011-08-31 |
アプライド モレキュラー エボリューション，インコーポレイテッド |
Ｆｃ領域変異体
|
|
EP1750754A4
(en)
|
2004-03-31 |
2010-09-22 |
Centocor Ortho Biotech Inc |
HUMAN GLP-1 MIMETIC BODIES, COMPOSITIONS, METHODS AND USES
|
|
US8642743B2
(en)
|
2004-04-06 |
2014-02-04 |
Affibody Ab |
Method for reducing the immune response to a biologically active protein
|
|
EP1747237A4
(en)
|
2004-04-16 |
2008-05-21 |
Macrogenics Inc |
SPECIFIC GAMMA FC ANTIBODIES AND METHODS OF USING THE SAME
|
|
CA2565874C
(en)
|
2004-05-10 |
2017-10-03 |
Macrogenics, Inc. |
Humanized fc.gamma.riib-specific antibodies and methods of use thereof
|
|
US7432419B2
(en)
|
2004-05-14 |
2008-10-07 |
Los Alamos National Security, Llc |
Compositions and methods for the treatment of Pierce's disease
|
|
EP1771205B1
(en)
|
2004-06-18 |
2016-10-26 |
Ambrx, Inc. |
Novel antigen-binding polypeptides and their uses
|
|
BRPI0514068B8
(pt)
|
2004-08-04 |
2021-05-25 |
Applied Molecular Evolution Inc |
anticorpo anti-cd20, e, composição farmacêutica
|
|
US20080038280A1
(en)
|
2004-10-14 |
2008-02-14 |
Government Of The United States Of America |
A32 Monoclonal Antibody Fusion Proteins For Use As Hiv Inhibitors And Vaccines
|
|
AU2005335714B2
(en)
|
2004-11-10 |
2012-07-26 |
Macrogenics, Inc. |
Engineering Fc antibody regions to confer effector function
|
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US20060193849A1
(en)
|
2005-02-25 |
2006-08-31 |
Antisoma Plc |
Biological materials and uses thereof
|
|
AU2005333155B2
(en)
|
2005-03-14 |
2011-11-17 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies against Hendra and Nipah viruses
|
|
JP5838021B2
(ja)
|
2005-04-15 |
2015-12-24 |
マクロジェニクス，インコーポレーテッド |
共有結合型ダイアボディとその使用
|
|
US9963510B2
(en)
|
2005-04-15 |
2018-05-08 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
US9284375B2
(en)
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
DK2573114T3
(en)
|
2005-08-10 |
2016-07-04 |
Macrogenics Inc |
The identification and production of antibodies with variant Fc regions, and methods of using same
|
|
US8236308B2
(en)
|
2005-10-11 |
2012-08-07 |
Micromet Ag |
Composition comprising cross-species-specific antibodies and uses thereof
|
|
JP5427027B2
(ja)
|
2006-05-03 |
2014-02-26 |
ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド，ア・ボディー・コーポレイト |
Ｃｄ４０アゴニスト抗体／ｉ型インターフェロン相乗性アジュバントの結合体、それを含む複合体、および細胞性免疫を強化する治療としてのその使用
|
|
WO2007130493A2
(en)
|
2006-05-03 |
2007-11-15 |
Regents Of The University Of Colorado |
Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
|
|
CA2660592C
(en)
|
2006-05-26 |
2016-07-12 |
Macrogenics, Inc. |
Humanized fc.gamma.riib-specific antibodies and methods of use thereof
|
|
JP2010519186A
(ja)
|
2007-02-19 |
2010-06-03 |
スミスクライン ビーチャム コーポレーション |
免疫調節物質としてのプリン誘導体
|
|
EP2158221B1
(en)
|
2007-06-21 |
2018-08-29 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
|
EP2209810A1
(en)
|
2007-10-15 |
2010-07-28 |
King's College London |
Viral therapeutic
|
|
MX2010004892A
(es)
|
2007-10-31 |
2010-08-10 |
Scripps Research Inst |
Terapia de combinacion para tratar infecciones virales persistentes.
|
|
WO2009117030A2
(en)
|
2007-12-19 |
2009-09-24 |
Macrogenics, Inc. |
Improved compositions for the prevention and treatment of smallpox
|
|
CA2719201A1
(en)
|
2008-03-28 |
2009-10-01 |
Sea Lane Biotechnologies, Llc. |
Neutralizing molecules to viral antigens
|
|
SG189730A1
(en)
|
2008-04-02 |
2013-05-31 |
Macrogenics Inc |
Her2/neu-specific antibodies and methods of using same
|
|
WO2010033279A2
(en)
|
2008-06-04 |
2010-03-25 |
Macrogenics, Inc. |
Antibodies with altered binding to fcrn and methods of using same
|
|
US20100040601A1
(en)
|
2008-06-10 |
2010-02-18 |
Cantin Edouard M |
Compositions and methods for treating herpes simplex virus infections and related diseases
|
|
JP5734201B2
(ja)
*
|
2008-12-19 |
2015-06-17 |
マクロジェニクス，インコーポレーテッド |
共有結合型ダイアボディ及びその使用
|
|
US8211866B2
(en)
|
2009-01-14 |
2012-07-03 |
Children's Research Institute, Children's National Medical Center |
Methods and compositions for treating HIV infection
|
|
EP2406387A4
(en)
|
2009-03-09 |
2013-04-17 |
Tvax Biomedical I Llc |
CELL IMMUNOTHERAPY FOR INFECTION DISEASES
|
|
US20110033389A1
(en)
|
2009-04-29 |
2011-02-10 |
Zhifeng Chen |
Modified antibodies for passive immunotherapy
|
|
CN102459332B
(zh)
|
2009-06-05 |
2015-08-19 |
埃博灵克斯股份有限公司 |
用于预防和/或治疗呼吸道感染的单价、二价和三价抗人呼吸道合胞病毒(hrsv)纳米抗体构建体
|
|
TWI507525B
(zh)
|
2009-06-26 |
2015-11-11 |
Regeneron Pharma |
具天然免疫球蛋白形式之易分離的雙專一性抗體
|
|
MX2012001882A
(es)
|
2009-08-13 |
2012-04-11 |
Crucell Holland Bv |
Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
|
|
MX2012004029A
(es)
|
2009-10-07 |
2012-05-08 |
Macrogenics Inc |
Polipeptidos que contienen la region fc que exhiben funcion efectora mejorada debido a alteraciones del grado de fucosilacion, y metodos para su uso.
|
|
US8999398B2
(en)
|
2009-11-06 |
2015-04-07 |
Transtarget Inc. |
Polyclonal bispecific antibody compositions and method of use
|
|
CA3040276A1
(en)
|
2009-12-02 |
2011-06-09 |
Imaginab, Inc. |
J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
|
|
US8663950B2
(en)
|
2010-01-11 |
2014-03-04 |
Arizona Board Of Regents |
Production of a monoclonal antibody therapeutic against west nile virus in plants
|
|
WO2011133886A2
(en)
|
2010-04-23 |
2011-10-27 |
Genentech, Inc. |
Production of heteromultimeric proteins
|
|
BR112013000452A2
(pt)
|
2010-07-09 |
2020-02-11 |
Affibody Ab |
Polipeptídeo de ligação de albumina, proteína de fusão ou conjugado, polinucleotídeo, método para produzir um polipeptídeo, composição, método para a preparação de uma composição, e, método para aumentar a solubilidade de um composto
|
|
ES2667100T3
(es)
|
2010-08-02 |
2018-05-09 |
Macrogenics, Inc. |
Diacuerpos covalentes y sus usos
|
|
CA3201524C
(en)
|
2010-08-31 |
2026-01-13 |
International Aids Vaccine Initiative |
Human immunodeficiency virus (hiv)-neutralizing antibodies
|
|
JP2014500712A
(ja)
|
2010-11-02 |
2014-01-16 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリンおよびその使用
|
|
AR085138A1
(es)
|
2011-02-04 |
2013-09-11 |
Genentech Inc |
VARIANTES DE Fc Y METODOS PARA SU PRODUCCION
|
|
WO2012143524A2
(en)
|
2011-04-20 |
2012-10-26 |
Genmab A/S |
Bispecific antibodies against her2 and cd3
|
|
US9376495B2
(en)
|
2011-05-21 |
2016-06-28 |
Macrogenics, Inc. |
Deimmunized serum-binding domains and their use in extending serum half-life
|
|
WO2012162067A2
(en)
*
|
2011-05-21 |
2012-11-29 |
Macrogenics, Inc. |
Cd3-binding molecules capable of binding to human and non-human cd3
|
|
SG195196A1
(en)
|
2011-05-27 |
2013-12-30 |
Dutalys |
Dual targeting
|
|
WO2013163427A1
(en)
|
2012-04-25 |
2013-10-31 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Antibodies to treat hiv-1 infection
|
|
US9879068B2
(en)
|
2012-06-21 |
2018-01-30 |
California Institute Of Technology |
Antibodies targeting HIV escape mutants
|
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
|
WO2014052620A1
(en)
*
|
2012-09-26 |
2014-04-03 |
Duke University |
Adcc-mediating antibodies, combinations and uses thereof
|
|
JO3532B1
(ar)
|
2013-03-13 |
2020-07-05 |
Regeneron Pharma |
الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
|
|
CA2906566C
(en)
|
2013-03-14 |
2024-09-10 |
Macrogenics, Inc. |
Immunoreactive bispecific molecules at immune effector cells expressing an activation receptor
|
|
UA116479C2
(uk)
|
2013-08-09 |
2018-03-26 |
Макродженікс, Інк. |
БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
|
|
EP2839842A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
|
|
EP2840091A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
|
|
WO2015048462A1
(en)
|
2013-09-27 |
2015-04-02 |
Duke University |
Human monoclonal antibodies
|
|
US10647768B2
(en)
|
2014-05-29 |
2020-05-12 |
Macrogenics, Inc. |
Multi-chain polypeptide-containing tri-specific binding molecules
|
|
EA201790719A1
(ru)
|
2014-09-26 |
2017-07-31 |
Макродженикс, Инк. |
Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
|
|
WO2016054101A1
(en)
|
2014-09-29 |
2016-04-07 |
Duke University |
Bispecific molecules comprising an hiv-1 envelope targeting arm
|